COMPASS Pathways Plc - Q1 2021 Financial Summary
Business Context and Reporting Period
This Form 6-K filing covers the unaudited interim condensed consolidated financial statements for the three months ended March 31, 2021. COMPASS Pathways Plc is a clinical-stage mental health care company developing psilocybin therapy (COMP360) for treatment-resistant depression (TRD). The company has no approved therapeutic candidates and has not generated any revenue to date. Operations are funded primarily through equity offerings and convertible notes.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2021 | Q1 2020 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(12,715) | $(8,585) |
| Net Loss Per Share (Basic & Diluted) | $(0.35) | $(0.93) |
| Operating Expenses | $13,602 | $8,705 |
| Cash and Cash Equivalents (End of Period) | $179,520 | $18,389 |
| Net Cash Used in Operating Activities | $(13,778) | $(4,460) |
| Accumulated Deficit | $(110,614) | $(46,150) |
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses rose by $4.9 million (56%) to $13.6 million.
- Research & Development (R&D): Increased by $1.7 million to $6.9 million, driven by higher clinical trial costs and personnel expenses.
- General & Administrative (G&A): Increased by $3.2 million to $6.7 million, primarily due to higher personnel costs, legal/professional fees associated with public company status, and facility expenses.
- Foreign Exchange Impact: The company recorded a foreign exchange loss of $0.6 million in Q1 2021, compared to a gain of $0.1 million in Q1 2020. This was largely due to the translation of U.S. dollar cash balances (from IPO proceeds) against the functional currency (Pound Sterling).
- Convertible Notes: Unlike Q1 2020, there were no fair value changes on convertible notes in Q1 2021 as the notes were converted to preferred shares in April 2020.
- R&D Tax Credit: The benefit from UK R&D tax credits increased to $1.6 million in Q1 2021 from $1.1 million in Q1 2020.
Outlook, Risks, and Subsequent Events
- Liquidity and Runway: As of March 31, 2021, the company held $179.5 million in cash. Management believes this, combined with proceeds from a subsequent offering, is sufficient to fund operations through 2023.
- Subsequent Financing: On May 4, 2021, the company completed an underwritten public offering of 4,000,000 ADSs at $36.00 per ADS, raising net proceeds of approximately $135.4 million.
- Clinical Development: The company is conducting a Phase IIb trial for COMP360. Data is expected in late 2021. Enrollment has been delayed by the COVID-19 pandemic.
- Risks: Key risks include the inability to raise additional capital, delays in clinical trials due to the pandemic, regulatory hurdles for psilocybin therapy, and the uncertainty of commercialization. The company expects to continue incurring significant losses for the foreseeable future.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $13.8 million quarterly cash burn from operations against the $179.5 million cash balance.
- Clinical Trial Progress: Confirm the status of the Phase IIb trial enrollment and the timeline for late 2021 data readout, considering pandemic-related delays.
- Capital Requirements: Assess the need for future financing beyond the May 2021 follow-on offering to reach commercialization.
- Regulatory Pathway: Monitor updates on the scheduling of psilocybin by the DEA and regulatory approvals from the FDA and EMA.
- Foreign Exchange Exposure: Evaluate the impact of GBP/USD fluctuations on future financial reporting given the company's UK functional currency and USD cash holdings.